About the Nova 301 trial
The Nova 301 Trial will evaluate the safety, effectiveness and immune response of a messenger RNA (mRNA) -based investigational vaccine aimed at preventing norovirus disease. The investigational vaccine, mRNA-1403, has been previously studied in Phase 1 and 2 clinical trials. You cannot get norovirus from the investigational vaccine. By participating in this Phase 3 trial, you play an important part in the development of a potential new vaccine for an illness that currently has none.
Who can join?
This clinical trial is looking for adult participants. Potential participants must:
- Be 18 years of age or older.
- Be in good health or have a well-controlled chronic medical condition.
- Not be pregnant or planning on becoming pregnant for at least 3 months following the dosing visit.
This study is fully recruited and is in the follow-up phase.
What is Norovirus?
You may have unknowingly had norovirus before but confused it with “food poisoning” or the “stomach bug.” You’ll likely remember if you’ve had it: symptoms most commonly include sudden nausea, vomiting and diarrhoea. These symptoms usually last for 1 to 3 days. In severe cases, these symptoms can lead to dehydration, which may require hospitalisation or IV fluids.
Norovirus spreads quickly in places where people are in close proximity, such as:
- Day care centres
- Retirement communitites
- Cruise ships
- Hospitals
- Restaurants
The Doherty Institute Vaccine Research Group are excited about a new vaccine trial for Norovirus.
Contact
For more information and to volunteer please contact:
Email: virgo-studies@unimelb.edu.au
Phone: +61 3 8344 9325 or +61 4 1832 2346
Principal Investigator